Australian life sciences company (ASX:OPT) has reported negative outcomes from its pivotal Phase 3 clinical trial involving the combination of its sozinibercept with Bayer's EYLEA (aflibercept) for treating wet age-related macular degeneration. …
Australian eye therapy company now focused on survival after clinical trial result
March 25, 2025 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - -
Island secures USAMRIID partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News -
New report highlights the potential health-system benefits of pharmacist prescribing
June 9, 2026 - - Latest News